Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 14Gynecologic 2Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Ovarian Neoplasms 13Uterine Cervical Neoplasms 9Stomach Neoplasms 9Colorectal Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 6Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Endometrial Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Breast Neoplasms 4Prostatic Neoplasms 3Lung Neoplasms 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Sarcoma 2Rectal Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Appendiceal Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Recurrence 1Peritoneal Neoplasms 1

Interventions

pembrolizumab 13Nivolumab 6Gemcitabine 5Paclitaxel 4Cisplatin 4Magnetic Resonance Spectroscopy 3Ipilimumab 3Fluorouracil 3Fluorodeoxyglucose F18 3Carboplatin 3spartalizumab 2fludarabine 2budigalimab 2Oxaliplatin 2Leucovorin 2Irinotecan 2FAPI-46 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2Bevacizumab 2venetoclax 1ulixertinib 1tislelizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Irinotecan × Gynecologic × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡